Drug Profile
Research programme: immunotherapeutics - CoImmune
Alternative Names: C.I.K.-CAR.CD23; C.I.K.-CAR.CD33Latest Information Update: 21 Dec 2021
Price :
$50
*
At a glance
- Originator University of Milan Bicocca
- Developer Formula Pharmaceutical
- Class
- Mechanism of Action Cytokine-induced killer cell replacements; IgE receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 15 Dec 2021 CoImmune plans a clinical trial for Acute-myeloid-leukaemia and Precursor-cell-lymphoblastic-leukaemia-lymphoma
- 17 Nov 2021 CoImmune in-licenses Synthetic Immune Niche (SIN) technology from Yeda Research and Development Company Ltd
- 30 Apr 2020 CoImmune has merged into Formula Pharmaceuticals to form CoImmune.